title: Fexofenadine regulates nuclear factor-κB signaling and endoplasmic reticulum stress in intestinal epithelial cells and ameliorates acute and chronic colitis in mice.
abstract: The aim of this study was to evaluate the effect of fexofenadine on intestinal inflammation. HCT116 and COLO205 cells were pretreated with fexofenadine and then stimulated with tumor necrosis factor (TNF)-α. Interleukin (IL)-8 expression was determined by real-time reverse-transcription polymerase chain reaction (PCR) and enzyme-linked immunosorbent assay. DNA-binding activity of nuclear factor-κB was assessed by electrophoretic mobility shift assay. The molecular markers of endoplasmic reticulum (ER) stress were evaluated by Western blot analysis and PCR. In the acute colitis model, mice were given 4% dextran sulfate sodium (DSS) for 5 days with or without fexofenadine. IL-10(-/-) mice were used to evaluate the effect of fexofenadine on chronic colitis. Fexofenadine significantly inhibited the upregulated expression of IL-8 in HCT116 and COLO205 cells stimulated with TNF-α. Fexofenadine suppressed nuclear factor-κB DNA-binding activity. C/EBP homologous protein mRNA expression was enhanced in the presence of TNF-α, and it was dampened by pretreatment of fexofenadine. In addition, the induction of ER stress markers caspase-12 and p-eukaryotic initiation factor 2 (eIF2)-α was significantly suppressed by the pretreatment of fexofenadine. Administration of fexofenadine significantly reduced the severity of DSS-induced murine colitis, as assessed by the disease activity index, colon length, and histology. In addition, the DSS-induced phospho-IκB kinase activation was significantly decreased in fexofenadine-pretreated mice. Finally, fexofenadine significantly reduced the severity of colitis and the immunoreactivity of caspase-12 and p-eIF2-α in IL-10(-/-) mice as compared with controls. These results suggest that fexofenadine is a potential therapeutic agent for the treatment of inflammatory bowel disease.
authors.affiliation: Department of Internal Medicine, Seoul National University Boramae Hospital (S.-J.K., J.W.K., B.G.K., K.L.L.) and Liver Research Institute (J.C., J.S.K.), Seoul National University College of Medicine, Seoul, Korea.
authors.forename: Seong-Joon
authors.initials: SJ
authors.lastname: Koh
authors.affiliation: Department of Internal Medicine, Seoul National University Boramae Hospital (S.-J.K., J.W.K., B.G.K., K.L.L.) and Liver Research Institute (J.C., J.S.K.), Seoul National University College of Medicine, Seoul, Korea.
authors.forename: Ji Won
authors.initials: JW
authors.lastname: Kim
authors.affiliation: Department of Internal Medicine, Seoul National University Boramae Hospital (S.-J.K., J.W.K., B.G.K., K.L.L.) and Liver Research Institute (J.C., J.S.K.), Seoul National University College of Medicine, Seoul, Korea.
authors.forename: Byeong Gwan
authors.initials: BG
authors.lastname: Kim
authors.affiliation: Department of Internal Medicine, Seoul National University Boramae Hospital (S.-J.K., J.W.K., B.G.K., K.L.L.) and Liver Research Institute (J.C., J.S.K.), Seoul National University College of Medicine, Seoul, Korea.
authors.forename: Kook Lae
authors.initials: KL
authors.lastname: Lee
authors.affiliation: Department of Internal Medicine, Seoul National University Boramae Hospital (S.-J.K., J.W.K., B.G.K., K.L.L.) and Liver Research Institute (J.C., J.S.K.), Seoul National University College of Medicine, Seoul, Korea.
authors.forename: Jaeyoung
authors.initials: J
authors.lastname: Chun
authors.affiliation: Department of Internal Medicine, Seoul National University Boramae Hospital (S.-J.K., J.W.K., B.G.K., K.L.L.) and Liver Research Institute (J.C., J.S.K.), Seoul National University College of Medicine, Seoul, Korea jooskim@snu.ac.kr.
authors.forename: Joo Sung
authors.initials: JS
authors.lastname: Kim
mesh_terms: D000208:Acute Disease; D000818:Animals; D002908:Chronic Disease; D003092:Colitis / Q000188:drug therapy* / Q000378:metabolism* / Q000473:pathology; D059865:Endoplasmic Reticulum Stress / Q000187:drug effects / Q000502:physiology*; D005260:Female; D045325:HCT116 Cells; D006801:Humans; D007413:Intestinal Mucosa / Q000187:drug effects / Q000378:metabolism* / Q000473:pathology; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D018345:Mice, Knockout; D016328:NF-kappa B / Q000502:physiology*; D016593:Terfenadine / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use
chemical_list: D016328:NF-kappa B; D016593:Terfenadine; C093230:fexofenadine